African genomics research company advancing precision medicine through genetic research focused on African populations.
54gene was a pioneering genomics company focused on addressing the underrepresentation of African genetic diversity in global research. The company built extensive biobanks and conducted genomic research to advance precision medicine for African populations. 54gene aimed to improve drug discovery and clinical trial outcomes by including more diverse genetic data. Despite raising significant funding and building important research capabilities, the company faced challenges and underwent restructuring in 2023.
54gene has received investment from 2 venture capital firms.
African genomics research company advancing precision medicine through genetic research focused on African populations.
54gene has received investment from Future Africa, Ingressive Capital. These venture capital firms and investors provide both capital and strategic support.
54gene has raised $45M in total funding, with their most recent round being a Series B. The company operates in the Biotech sector.
54gene was founded in 2019 and is headquartered in Lagos, Nigeria.
54gene operates in the Biotech sector. African genomics research company advancing precision medicine through genetic research focused on African populations.
